Drug General Information (ID: DDIMQY60ZG)
Drug Name			Sorafenib		Drug Info		Carboplatin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Antineoplastics
Structure

Mechanism of Sorafenib-Carboplatin Interaction (Severity Level: Major)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Sorafenib				Carboplatin
Mechanism		Sorafenib				Increase the risk of death in combination with sorafenib
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Sorafenib when combined with Carboplatin

Recommended Action
Management		The concomitant use of sorafenib with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Caution may be advisable when this combination is used in other malignancies.

References
1	Flaherty KT, Schiller J, Schuchter, et al "A phrase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel." Clin Cancer Res 14 (2008): 4836-42. [PMID: 18676756]
2	Polcher M, Eckhardt M, Coch C, et al. "Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer." Cancer Chemother Pharmacol 66 (2010): 203-7.[PMID: 20204367]
3	Scagliotti G, Novello S, von Pawel J, et al. "Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer." J Clin Oncol 28 (2010): 1835-42.[PMID: 20212250]